Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + daratumumab + dexamethasone
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
The combination of zanubrutinib, daratumumab, and dexamethasone is a non-existent and unverified therapeutic regimen. Individually, zanubrutinib is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor developed by BeiGene for B-cell malignancies; daratumumab is an anti-CD38 monoclonal antibody developed by Janssen for multiple myeloma and light chain (AL) amyloidosis; and dexamethasone is a synthetic glucocorticoid corticosteroid used broadly in oncology. There are no public clinical trials or drug development programs evaluating these three agents in combination.
02
Targets
CD38 (Cluster of Differentiation 38)GR (Glucocorticoid receptor)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on zanubrutinib + daratumumab + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + daratumumab + dexamethasone.